Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03421288

Recruitment Status : Recruiting

First Posted : February 5, 2018

Last Update Posted : August 14, 2023

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Roche Pharma AG

Information provided by (Responsible Party):

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	May 31, 2027
Estimated Study Completion Date :	December 31, 2027

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304.

To Top